Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Halozyme Therapeutics, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
halozyme.comAI Executive Summary
AI-powered analysis of 8-K filing content
James Daly was elected to Halozyme Therapeutics' Board of Directors on September 28, 2026, filling a vacancy with a term extending to 2029. This board expansion brings new expertise and perspectives to the company's governance structure.
Key Takeaways
James Daly joins the Board of Directors effective September 28, 2026, with a term ending at the 2029 annual stockholder meeting
Daly will receive compensation including cash retainers, restricted stock, and stock option awards under the company's non-employee director compensation program
2 more takeaways
Filing Overview
What This Means
Halozyme Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.